Search Results - "Variya, Ketan"
-
1
-
2
Abstract 1616: Preclinical characterization of KSHN001126, a novel, differentiated and steroidal oral selective estrogen receptor degrader (SERD)
Published in Cancer research (Chicago, Ill.) (04-04-2023)“…Abstract Fulvestrant (FLV) (Faslodex®) is the only clinically approved steroidal SERD that requires painful intramuscular administration. Several oral SERDs…”
Get full text
Journal Article -
3
Abstract 4043: KSHN001034: An intramuscular prodrug of fulvestrant to treat estrogen-receptor (ER) positive advanced metastatic breast cancer
Published in Cancer research (Chicago, Ill.) (15-06-2022)“…Abstract Purpose: Breast cancer (BC) remains a considerable health concern, with over 75% of total cases accounting for ER+ BC. Fulvestrant, a selective…”
Get full text
Journal Article -
4
Abstract 3077: Pharmacological profiling of KSHN001034 - A novel prodrug of Fulvestrant with improved efficacy
Published in Cancer research (Chicago, Ill.) (04-04-2023)“…Abstract Purpose: KSHN001034, a Fulvestrant (FLV) prodrug, was developed to enhance solubility and achieve higher FLV plasma exposures. Currently, Faslodex®…”
Get full text
Journal Article -
5
ACUTE TOXICITY EVALUATION OF PROTODIOSCIN RICH EXTRACT OF TRIGONELLA FOENUM-GRAECUM L IN RATS
Published in Asian journal of pharmaceutical and clinical research (01-12-2016)“…ABSTRACTObjectives: The objective of this study was to investigate the acute toxicity of standardized protodioscin rich extract (PRE) of Trigonella…”
Get full text
Journal Article